Medifast (MED) Change in Accured Expenses (2010 - 2026)

Medifast has reported Change in Accured Expenses for 17 years, with the latest figure at -$1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 75.84% year-over-year to -$1.4 million; the trailing twelve-month figure through Mar 2026 stood at -$19.4 million (up 22.77% YoY), and the FY2025 full-year result was -$23.9 million, up 31.67% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$1.4 million, up from -$4.3 million in the prior quarter.
• The five-year high for Change in Accured Expenses was -$364000.0 in Q4 2023, with the low at -$21.9 million in Q1 2023.
• Historically, Change in Accured Expenses has averaged -$7.9 million across 5 years, with a median of -$6.1 million in 2022.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses surged 97.63% — and 2024, when it slumped 2982.14%.
• Medifast's Change in Accured Expenses stood at -$15.3 million in 2022, then surged by 97.63% to -$364000.0 in 2023, then tumbled by 2982.14% to -$11.2 million in 2024, then soared by 61.65% to -$4.3 million in 2025, then soared by 66.33% to -$1.4 million in 2026.
• The last three Change in Accured Expenses figures came in at -$1.4 million (Q1 2026), -$4.3 million (Q4 2025), and -$516000.0 (Q3 2025), per Business Quant data.